Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The decision makers at the FDA didn't buy hgen stock
Any chance they loaded up on mrna stock?
What do the MMs have to gain by always trying to get shares to give the IIs the price they want? Maybe the CDMO MMs and the IIs have a relationship that extends to other stocks besides CDMO. The MMs benefit by always having buyers for their inventories in different stocks and they are reciprocating by helping the IIs buy CDMO shares at lower prices. Do you think that the CDMO pps would be higher had it not been for all these IIs buying in with the MMs helping them get shares at lower prices?
Also, my two IRA accounts are cash accounts and I believe they cannot be changed to margin accounts. Most of my shares are in my IRA accounts.
I had a margin account with Scottrade and when it was bought out by TDameritrade they changed it to a cash account. I opened a small margin account at TDameritrade and about two months ago they changed it to a cash account because I reside abroad now. I got burned that monday in 2012 when we all got an 80% haircut because I had purchased some calls on margin that had gone up quite a bit. Got a margin call and had to sell some stock.
If you don't have a margin account your shares cannot be borrowed. Haven't checked if that has changed.
It looks like the IIs are onto to something we don't know about. My best guess is a buyout leaked to them.
We are being bombarded with so much information that it makes it kind of hard to sort out the truth from bad information with an agenda behind it.But the article you linked to sounds very credible to me.
Scary. Blood clots that occur in the capillary caused by the protein spikes that attach temselves to the capillary walls which are smooth to facilitate the blood flow. The doctor said these microscopic blood clots show up only on a d-dimer blood test. He said they showed on 62% of the vaccinated sample he tested. What could be the consequences of these microscopic blood clots? More time is obviously needed to find out. I hope they don't cause any problems.
"the problem is that we seem to be dealing with two sources that have a good reputation, both choosing the opposite side of the medal".
It is obvious that there is an agenda behind many studies that have to do with supplements or even certain foods and diseases.
There is a lot of money to be made or lost if some competing product,food or any other thing is effective or not for the same health condition or disease your company makes a product for.
Somebody pays for those studies and they expect certain results. This goes a long way in explaining why some study show one thing and other studies the opposite. How do we know that all of these studies are not manipulated? Are these studies overseen by some independent entity and are there even any such entities? If there are, they might be far and in between and we just won't know which ones are.
Link to NIH article whose director is Fauci. Must read for anyone interested in preventing and mitigating COVID 19 complications and other illnesses.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761047/
"Vitamin D Insufficiency May Account for Almost Nine of Ten COVID-19 Deaths: Time to Act. Comment on: “Vitamin D Deficiency and Outcome of COVID-19 Patients”."
Evidence from observational studies is accumulating, suggesting that the majority of deaths due to SARS-CoV-2 infections are statistically attributable to vitamin D insufficiency and could potentially be prevented by vitamin D supplementation. Given the dynamics of the COVID-19 pandemic, rational vitamin D supplementation whose safety has been proven in an extensive body of research should be promoted and initiated to limit the toll of the pandemic even before the final proof of efficacy in preventing COVID-19 deaths by randomized trials.
We read, with great interest, the recent article by Radujkovic et al. that reported associations between vitamin D deficiency (25(OH)D < 12 ng/mL) or insufficiency (25(OH)D < 20 ng/mL) and death in a cohort of 185 consecutive symptomatic SARS-CoV-2-positive patients admitted to the Medical University Hospital Heidelberg, who were diagnosed and treated between 18 March and 18 June 2020 [1]. In this cohort, 118 patients (64%) had vitamin D insufficiency at recruitment (including 41 patients with vitamin D deficiency), and 16 patients died of the infection. With a covariate-adjusted relative risk of death of 11.3, mortality was much higher among vitamin D insufficient patients than among other patients. When translated to the proportion of deaths in the population that is statistically attributable to vitamin D insufficiency (“population attributable risk proportion”), a key measure of public health relevance of risk factors [2], these results imply that 87% of COVID-19 deaths may be statistically attributed to vitamin D insufficiency and could potentially be avoided by eliminating vitamin D insufficiency.
Although results of an observational study, such as this one, need to be interpreted with caution, as done by the authors [1], due to the potential of residual confounding or reverse causality (i.e., vitamin D insufficiency resulting from poor health status at baseline rather than vice versa), it appears extremely unlikely that such a strong association in this prospective cohort study could be explained this way, in particular as the authors had adjusted for age, sex and comorbidity as potential confounders in their multivariate analysis. There are also multiple plausible mechanisms that may well explain the observed associations, such as increased concentrations of pro-inflammatory cytokines, as well as decreased concentrations of anti-inflammatory cytokines in vitamin D insufficiency [3,4]. Although final proof of causality and prevention of deaths by vitamin D supplementation would have to come from randomized trials which meanwhile have been initiated (e.g., [5]), the results of such trials will not be available in the short run. Given the dynamics of the COVID-19 pandemic and the proven safety of vitamin D supplementation, it therefore appears highly debatable and potentially even unethical to await results of such trials before public health action is taken. Besides other population-wide measures of prevention, widespread vitamin D3 supplementation at least for high-risk groups, such as older adults or people with relevant comorbidity, which has been proven by randomized controlled trials to be beneficial with respect to prevention of other acute respiratory infections and acute acerbation of asthma and chronic pulmonary disease [6,7,8,9,10], should be promoted. In addition, targeted vitamin D3 supplementation of people tested SARS-CoV-2-positive may be warranted.
What other options does Green have but to finish the expansion under way. I would say none.
I remember the message that he posted the day that Tarvacin or Bavi was going to be injected in the trial participants(don't remember if the name had already been changed).He went on to say: Today Tarvacin will be flowing for the first time ever in the veins of some people...Don't remember any of the rest that he wrote but I remember that what he wrote generated a lot of excitement on the RB message board.
[img][/img]
Unlike PPHM, CDMO keeps going like a choo choo train. Slow and steady with no jack rabbit starts followed by the inevitable pullbacks.
Was it a buy or a sell?
Now we know where Jeanette Bleeker has been working. This might be a sabotage a la Bavi. GlobeBio will get on the case and report all the connections and links that he finds.
After the exceptional quarter on all fronts as per Nick the stock could have gone significantly higher than 20. Nick and the BOD knew this. When you sell through yhe ATM you try to do it so as to minimize the decline in price. We saw how fast they tanked the stock.
Would using the ATM have been worse or better than this? We still going to have dilution.
"Holders of the notes will have the right to exchange their notes for shares of the company’s common stock in certain circumstances and during specified periods. "
We need to hear the details of this.
How do they figure the earnings estimates for every company?
I didn't know it had an expiration date.
The poison pill is supposed to do that.
Rinse and repeat.
Exosomes cancer drug cures 29 out of 30 COVID patients.
https://www.wfmynews2.com/article/news/health/coronavirus/covid-coronavirus-treatment-israel-exo-cd24-cytokine-storm-research-new/83-4752e379-3ca7-47b1-a3f6-b0955faa3642
Viewer Jon Thomas asks us to verify: Did cancer drug EXO-CD24 cure 30 Covid-19 patients in Israel?
Our sources for this are the Jewish News Syndicate and the Yale School of Medicine.
According to the Jewish News Syndicate, Israel's Prime Minister met with researchers behind EXO-CD24 Monday saying "If this succeeds, it will be huge, simply huge. This little thing could change the fate of humanity."
The researchers say they gave the drug to 30 patients with moderate-to-severe cases of COVID-19, and by 5 days later 29 of the 30 patients had been released from the hospital. The last patient was released after more time.
This research is still in the very early stages. It needs to be reviewed by medical peers around the world.
But we do know: the drug does not cure you of COVID-19 - meaning it does not get rid of the COVID-19 in your body. Instead, the medicine treats one of the most deadly symptoms: a cytokine storm. That's when your immune system is kicked into overdrive and actually does more harm than good according to a video posted online by the Yale School of Medicine.
"It is thought that it is really the overdrive of the immune response that's leading to the severe cases of COVID-19. Instead of helping the host cope with the infection, the cytokines can actually cause damage to the tissue. such as breaking down the protective layer of the lungs," the video says.
So the new drug did not cure 30 patients in Israel of COVID-19, but we can verify it is a possible new treatment for a COVID-19 symptom.
Have something you want us to verify? Let Ben Briscoe know on Twitter.
How is your 4 dollar prediction going?
You're spreading false information. Bavi was sold for 8 million PLUS 95 millions if certain milestones are reached PLUS 15% royalties PLUS manufacturing rights. If no milestones are met, we get nothing. If Bavi, currently in two phase II combination trials, is commercialized we get 15% in royalties plus the manufacturing rights which will add to the other drugs AVID is or will be manufacturing at that time. If one of BAVI phase II trials or both progress to commercialization who knows how many more combination trials leading to more commercializations there will be. In order for Oncologie or Oncxerna to pay 95 millions in milestones they would have to rake in many more times that. To say that BAVI is a failure is a joke.
"Treatment with bavituximab and KEYTRUDA also generated a complete response in 20% (2/10) of patients who were PD-L1, CPS<1; a patient population where KEYTRUDA historically generates very low complete responses. In terms of response duration, all confirmed responders remain in the trial, with the longest responder approaching one-year of duration of response." Is KEYTRUDA a failure too?
https://www.globenewswire.com/news-release/2020/09/18/2095763/0/en/Oncologie-Announces-New-Data-and-Analyses-from-Clinical-Programs-and-Name-Change-to-OncXerna-Therapeutics.html
Homework for the naysayers:https://oncxerna.com/wp-content/uploads/2020/09/2020-ESMO-Oncologie-ONCG100-poster-FINAL.pdf
HALO down 7.2%. It appears to be due to traders but can they cause such a big pps movement in a stock like HALO. Wouldn't it be nice if Halozyme took a stake in AVID.
How has the pps benefited from the institution investments that we have had? It looks like the pps is lower because of the increase in institutional investments we have had. Every time an institution wants to buy in they always buy in below the market price at that time. They give their limit order below the current price to the MMs who lower the price. The MMs can lower the pps at will or so it seems to pick up shares by scaring retail into selling and triggering the stop losses. When they pick all of the shares the institutional buyer wants they sell them to them at a hefty profit while the institutional investors gets its shares. This is something NASDAQ must be proud of.
When the institutional investors want to sell they get no cooperation from the MMs and we see the pps take a big and sharp plunge. And those shares that were sold en masse were shares that were in strong hands. Retail loses again.
I if I remember correctly the last new institutional investor didn't buy in below the market price. It could be they are not part of the club.
How can you have bids when you don't put it on sale? They sold it to the first buyer. How could someone else bid after the sale? Why would Merck run two phase II trials with a failed drug if nothing good could come out it? Are drugs that are in two different combination phase II trials with a major pharma worthless now?
Lifshitz Law Firm, P.C. Announces Investigation of Immunomedics, Inc. (NASDAQ: IMMU)
Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of Immunomedics to Gilead Sciences, Inc. for $88.00 per share in cash.
Wasn't there a breach of fiduciary duty when the IP was sold for 8 million plus 15% royalties and manufacturing rights to a company that materialized out of thin air in what? A couple of months?
It's quite possible that the investors were more interested in getting inside information that they could profit on rather than throwing their lot in with the company. If they realized that Mr. Green wasn't going to play ball with them, they decided to go hunting for another company they could play ball with.
If you are going to have a conference with any investors the first thing you should consider is what are the investors interested in? Making money is their game and what is the safest, best way for them to make money? Trading on inside information like we have seen with CDMO so many times except for this time.
Sorry to hear about your heart attack. Did you have a bypass or was a valve problem? Bypass operations work really well fortunately. Unlike cancer which doesn't have as a good a solution. We were hoping, still hope that Bavi would change that. Heart disease and cancer are the two top killers. Stroke. also caused by plaque, is another big killer.
Unwittingly, I went the route of prevention as far as heart disease and strokes go. I started taking 500-1000 mg of vitamin C in 1982-3. My cholesterol then, the firs time I got it checked, was 305. Never took statins and my cheolesterol was almost always very high. I was worried about my high cholesterol and my Dr prescribed statins for me a few times which I never took.About fifteen years ago, one of my Primary care doctors had me do a heart scan which showed that I had zero plaque. He then had me do a carotid ultrasound which also showed no plaque. Last year, I had another carotid ultrasound and the doctor was amazed that at my age, 63, I had no plaque at all.
According to some, the cause of plaque is lesions which develop in weak arterial walls because of lack of vitamin C. These lesions are sealed with cholesterol, calcium in order to prevent leaks. Read what Dr Rath says about it here. He wrote the book Why Animals Don't Get Heart Attacks But People Do.
https://www.dr-rath-foundation.org/2002/05/the-stanford-speech-eradicating-heart-disease/
As far as cancer, we don't have good choices right now. But there is a way to make chemotherapy safer just by fasting for three days before you have it done. Probably, it won't work for everybody but it's worth considering, I think.
https://immuno-oncologynews.com/2016/07/14/fasting-like-diet-may-naturally-help-cancer-patients/
“This (a fasting-like diet) could be a very inexpensive way to make a wide range of cancer cells more vulnerable to an attack by the immune cells, while also making the cancer more sensitive to the chemotherapy,” said Longo.
Previous work had shown that a short-term fast starves cancer cells and facilitates the chemotherapy drugs to better target them. Also, a low-calorie, fasting-like diet can slow the progression of multiple sclerosis by killing “bad cells” and generating new healthy ones."
Maybe he became CEO just in the Nick of time before we start seeing a lot of Green. No more red please or just a little so as not to make any difference.
Do you think that the old BOD has a stake in Oncologie? They sure went away very quietly after Stafford opened his mouth. Maybe they have a stake in or own one of the companies that funded Oncologie. It was very strange how quickly the IP was sold to Oncologie and how quickly Oncologie let Merck start the combo trials with Bavi. It looks like the sale and combo trials were pre-arranged by somebodies. Not to mention how quickly Oncologie was formed.
I remember some on this board were afraid that the old BOD was going to take PPHM private. Isn't that what happened? The IP is in private hands now and we know nothing about the upfront and milestone payments Oncologie got and will get. Plus Oncologie gets the lion share, 85%, we get a meager 15% plus manufacturing rights which we don't know how favorable they will be.And to those who were happy we no longer had to incur any R&D costs, so does Oncologie who smartly lets Merck or whoever else wants to do a combo trial pay for the R&D.
I don't think there is a more appropriate video.
Halo is correct in stating that there were no interruptions at their two CDMOs due to COVID 19. That is what their investors were worried about. Why would they bring up the equipment failure if nobody asked about it? What I am worried about is Halo looking to replace AVID with a more reliable CDMO. We now wish Steve King was still here. No maintenance shutdowns or equipment failures during his tenure over many years.
What I like to know is who did their maintenance? Did they hire an outsider to do it or did they do it in house? Every time they hire an outsider to do something for them it backfires. The sabotaged phase II trial, the compensation that their legal team negotiated and signed in case of a compromised trial: it was only $500k I believe. And now maybe the scheduled maintenance that did not prevent the equipment failure.
In the meantime we are down to 5.46 or 6% on only 80k shares. Something doesn't jive. How can the MMs move the price down or up so much on so little volume? They are supposed to keep an inventory of the stocks they operate in to stabilize the price but they are taking advantage of every opportunity to make money on such wild price swings.
Everything is so corrupt now. Big pharma, predatory board members who follow their own agenda, Market Makers who probably make a lot more on walking stocks up and down than they do on the spreads, all of the governmental watchdog agencies, small businesses like auto repair shops who are so notorious for ripping off their customers, big businesses, scientists and researchers who publish studies that say what their paying sponsors want them to say and on and on with no end in sight.
Parallel Universes
do they exist
It's very easy to get the pps to 258. All you need is a 1 for 40 reverse stock split.
Your post was right on the money.
This also explains why and how they gave away the IP for so little in return. They have pals they take care of who in turn take care of them while always screwing the shareholders. We do not know and can only imagine how much Oncologie got upfront from Merck for letting them use Bavi in their two phase II combination trials. Ditto for the third phase II combination trial although Gliobastoma does not have as big a market. We spent $400 million to develop Bavi, Oncologie gets two unknown to us big payments upfront from Merck without having to spend any more money on R&D, they then get to keep 85% of the profits if and when the combination drugs get approved and are commercialized and they give us only 15% in royalties. We also get to manufacture Bavi which could be quite lucrative.
EXCEPT! I haven't read the contract between Oncologie and AVID! Who knows if the contract allows Oncologie to go to another manufacturer leaving AVID out in the cold? Like if they keep having equipment failures, maintenance shutdowns. Does anybody remember the contract PPHM signed with the company that was running the trial that would only give PPHM two millions if they screwed up the trial when the loss to PPHM was in the billions? Yeah, that is what Phase II drugs are worth and AbbieVie was going to pay 2 billions until they pulled out of the deal after the sabotage.
They way this new crew is behaving is so far so much like the old BOD. Afterall, they were picked by the old BOD and Ronin who turned out to be a brilliant:) savior for us along with Steve White who clammed up as fast as Stafford did.
"Are you going to tell me that NO companies kept the PPP loans they applied for, and were not prepared to challenge any possible probes into the legitimacy of their claim to it? Pul-eeze. Of course there are companies doing just that as we speak! It was a 50/50 bet at best on what Avid would do. In fact, being in the field they are in, they probably had a better chance of skating by keeping it than most! There was precious little risk in attempting to do so! Due diligence? Bah."
The reason is now very clear why the BOD didn't keep the loan even though the worst thing that could have happened would have been that they had to return the loan.
If they kept the loan there would not have been any insider trading when they returned the loan. They tipped off their pals again like you said before they let the rest of us know. We wondered why the pps went up all of the sudden and guessed that maybe the loan was returned while the inside traders were closing their positions and and taking their profits. Or maybe after they were tipped off that AVID got the loan they bought and then sold into strength thus closing their positions then with a profit. When they were tipped again that the loan was returned they could have profited a second time by selling short.
Insider traders are great investors! Let us remember these two:
"Ivan Frederick Boesky (born March 6, 1937) is a former American stock trader who became infamous for his prominent role in an insider trading scandal that occurred in the United States during the mid-1980s"
https://en.wikipedia.org/wiki/Ivan_Boesky
"Milken was indicted for racketeering and securities fraud in 1989 in an insider trading investigation."
https://en.wikipedia.org/wiki/Michael_Milken
Remember the song
every step you take, every move you make I'll be watching you.
With this crew it's every step we take, every move we make we'll be screwing you. We being the BOD, you being retail.
When this BOD took the step of accepting their BOD positions the first move they made was to screw retail by dumping the "worthless" IP assets ( Bavi, exosomes, Betabodies) for a cup of coffee (8 million and 15% royalties for Bavi, nothing for exosomes and Betabodies. They only had cost us $400 millions up to that point. Oncologie couln't contain itself with their newfound wealth which they parlayed into two phase two trials with a Merck cancer drug plus a third phase two trial for gliobastoma. And how much more to come will be there for Oncologie?
When the new BOD with tons of experience in the business took the step of doing an equipment maintenance they screwed the pps because of the shutdown. You would thing the maintenance would have prevented the equipment failure that followed and we don't even know yet the status (is one supposed to think that is what preventive or regular maintenance is for, preventing equipment failures?).
When they moved to operating the equipment, it failed and it screwed retail again with another pps dive instead of a rise that everyone was expecting. When they made the move to take a loan, they screwed retail again with another pps dive which we are seeing now because they had to return the loan or face serious consequences with the feds. Who would want that.
Should we be nervous about their next step or move now? Or what about a nice, unexpected surprise like we never had in my 18 years in this stock?
A rising tide will lift all boats except for the ones that have a hole in it. Which kind of boat are we with this BOD?